Overview
Intrapleural Fibrinolytic Therapy to Enhance Chemical Pleurodesis Enhance Chemical Pleurodesis
Status:
Recruiting
Recruiting
Trial end date:
2022-12-01
2022-12-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
Prospective Randomized Double-Blind Controlled Trial of Intrapleural Fibrinolytic Therapy to Enhance Chemical Pleurodesis versus Standard of care Talc therapy in patients with recurrent pleural effusion.Phase:
Phase 4Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Memorial Healthcare SystemCollaborator:
Genentech, Inc.Treatments:
Tissue Plasminogen Activator
Criteria
Inclusion Criteria:1. Age > 18 years
2. Symptomatic pleural effusion requiring intervention
3. Expected survival > 3 months
4. Written informed consent to trial participation
Exclusion Criteria:
1. Females who are pregnant or lactating
2. Inability to obtain consent from the patient or patient's designated representative.
3. Inability of the patient to comply with the protocol.
4. Previously documented adverse reaction to talc or cathflo activase.
5. Oral or intravenous steroid therapy